22 recruiting, 13 active not recruiting, 11 unknown, 8 completed. 31 Phase 2, 19 Phase 1, 4 Not applicable, 2 Phase 3, 1 Early Phase 1.
Follow Melanoma Stage IV: new trials by email Literature Review of Melanoma Stage IV trials Research Report on Melanoma Stage IV
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma Opdualag, Nivolumab - Cutaneous Melanoma, Melanoma Stage IV | Phase 2 | Recruiting | University Health Network, Toronto | 54 | 2026-11-30 | 2026-10-13 |
| Screening for Brain Metastases gadopiclenol (contrast agent), standard contrast agent - Lung Cancer Stage IV, Melanoma Stage IV | Phase 2 | Not yet recruiting | University of Zurich | 180 | 2026-09-01 | 2026-03-25 |
| NeoAdjuvant, Spare-Adjuvant (NASA) in Stage IIIB-IV (M1a) Melanoma Pembrolizumab, Ipilimumab plus nivolumab - Melanoma (Skin Cancer), Melanoma Stage Stage IIIB | Phase 2 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 55 | 2026-08-06 | 2026-09-30 |
| Urinary Microbiome as a Biomarker for Melanoma Diagnosis and Response Prediction to Systemic Tumour Therapy Melanoma Stage IV | Recruiting | Medical University of Graz | 50 | 2025-05-08 | 2026-06-09 | |
| To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma ADP-TILIL7, Cyclophosphamide, Fludarabine Phosphate - Melanoma Stage III, Melanoma Stage IV | Phase 1 | Recruiting | Inge Marie Svane | 10 | 2025-04-01 | 2025-08-24 |
| Clinical and Ultrasound Incidence of Rheumatologic Immune Related Adverse Events in Stage IIB-IV Melanoma Patients Joint ultrasonography, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 version 3.0 - Melanoma, Stage II, Melanoma Stage III | Not yet recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 100 | 2025-02-01 | 2025-01-17 | |
| Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma Pembrolizumab, Cyclophosphamide - Melanoma, Melanoma Stage III | Phase 2 | Recruiting | University of California, Irvine | 14 | 2024-12-23 | 2026-03-10 |
| A Study of VET3-TGI in Patients With Solid Tumors VET3-TGI, Atezolizumab - Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer | Phase 1 | Recruiting | KaliVir Immunotherapeutics | 60 | 2024-09-16 | 2026-04-07 |
| Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients L19IL2, L19TNF, L19IL2/L19TNF - Melanoma Stage III, Melanoma Stage IV | Phase 2 | Recruiting | Philogen S.p.A. | 162 | 2024-07-12 | 2026-09-02 |
| Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma Nivolumab, Nivolumab + Relatlimab, Ipilimumab - Melanoma Stage III, Melanoma Stage IV | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 90 | 2024-05-17 | 2026-04-01 |
| Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors GIM-531, Anti-PD-1 monoclonal antibody - Melanoma Stage IV, Solid Tumor | Phase 1 / Phase 2 | Recruiting | Georgiamune Inc | 117 | 2024-05-09 | 2026-08-14 |
| Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies MB-CART19.1, MB-CART20.1, MB-CART2019.1 - Melanoma Stage III, B-cell Non Hodgkin Lymphoma | Not applicable | Recruiting | Miltenyi Biomedicine GmbH | 40 | 2024-05-05 | 2026-10-09 |
| Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography - Melanoma, Melanoma Stage III | Recruiting | University of Wisconsin, Madison | 24 | 2024-01-30 | 2026-01-20 | |
| Metastatic Melanoma Patients on Immunotherapy With Nutritive Intervention Based on Mediterranean Diet Mediterranean Diet Intervention - Melanoma Stage Iv, Metastatic Melanoma | Not applicable | Unknown | University Hospital Rijeka | 30 | 2023-12-21 | 2024-02-01 |
| A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors KB707, Opdualag, KEYTRUDA ®( Pembrolizumab) - Cancer, Melanoma Stage III | Phase 1 / Phase 2 | Recruiting | Krystal Biotech, Inc. | 240 | 2023-10-31 | 2025-05-18 |
| MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma [203Pb]VMT01, [212Pb]VMT01, Nivolumab - Recurrent Melanoma (Skin), Metastatic Melanoma | Phase 1 / Phase 2 | Recruiting | Perspective Therapeutics | 300 | 2023-06-01 | 2026-10-13 |
| Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial nivolumab - Melanoma Stage IV, Melanoma Stage III | Not applicable | Recruiting | Erasmus Medical Center | 80 | 2023-02-01 | 2025-02-28 |
| Intrathecal Double Checkpoint Inhibition intrathecal nivolumab and intrathecal ipilimumab - Leptomeningeal Metastasis, Non-small Cell Lung Cancer Stage IV | Phase 1 | Active not recruiting | University of Zurich | 26 | 2022-11-25 | 2025-10-02 |
| A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma Regorafenib 40 MG Oral Tablet, Triplet therapy - Melanoma Stage III, Melanoma Stage IV | Phase 2 | Active not recruiting | Universitair Ziekenhuis Brussel | 48 | 2022-10-03 | 2026-09-30 |
| A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma EVX-01, Pembrolizumab 25 MG/ML - Melanoma Stage IV, Unresectable Melanoma | Phase 2 | Active not recruiting | Evaxion Biotech A/S | 17 | 2022-09-19 | 2025-09-22 |
Showing 20 of 60. Sign in to see all of them.
Melanoma (60) · Carcinoma, Non-Small-Cell Lung (7) · Neoplasm Metastasis (3) · Skin Neoplasms (3) · Brain Neoplasms (2) · Breast Neoplasms (2) · Carcinoma, Renal Cell (2) · Carcinoma, Squamous Cell (2) · Drug-Related Side Effects and Adverse Reactions (2) · Kidney Neoplasms (2) · Neoplasms (2) · Ovarian Neoplasms (2) · Prostatic Neoplasms (2) · Sarcoma (2) · Squamous Cell Carcinoma of Head and Neck (2)
Neoplasms by Histologic Type (60) · Neoplasms by Site (60) · Neoplasms, Germ Cell and Embryonal (60) · Neoplasms, Nerve Tissue (60) · Neuroectodermal Tumors (60) · Neuroendocrine Tumors (60) · Nevi and Melanomas (60) · Skin Diseases (60) · Skin and Connective Tissue Diseases (60) · Neoplasms (58) · Skin Neoplasms (57) · Lung Diseases (8) · Respiratory Tract Diseases (8) · Respiratory Tract Neoplasms (8) · Thoracic Neoplasms (8)
Nivolumab (14) · Ipilimumab (7) · pembrolizumab (6) · Cyclophosphamide (3) · Fecal Microbiota Transplantation (3) · Opdualag (3) · aldesleukin (3) · binimetinib (3) · Blood Specimen Collection (2) · Denosumab (2) · Injections (2) · Interleukin-2 (2) · encorafenib (2) · Axitinib (1) · Circulating Tumor DNA (1)
H. Lee Moffitt Cancer Center and Research Institute (3) · Evaxion Biotech A/S (2) · MelanomaPRO, Russia (2) · Peking University Cancer Hospital & Institute (2) · Perspective Therapeutics (2) · The Netherlands Cancer Institute (2) · UNC Lineberger Comprehensive Cancer Center (2) · University of Zurich (2) · Vastra Gotaland Region (2) · BioNTech SE (1) · Biocad (1) · Centre hospitalier de l'Université de Montréal (CHUM) (1) · Charite University, Berlin, Germany (1) · Dana-Farber Cancer Institute (1) · Diwakar Davar (1)
United States (24) · Australia (6) · Germany (6) · Italy (6) · United Kingdom (5) · Israel (4) · Netherlands (4) · Russia (4) · Austria (3) · Spain (3) · Switzerland (3) · Canada (2) · Norway (2) · Poland (2) · Sweden (2)
Ahmad Tarhini, MD, PhD (2) · Stergios Moschos, MD (2) · Abi Vainstein-Haras, MD (1) · Arielle Elkrief, MD (1) · Cecilie D Vestergaard, M.D. (1) · Charlotte Proby, MBBS,FRCP (1) · Danielle Bello (1) · David Chien, MD (1) · Davorin Herceg, MD, PhD (1) · Diwakar Davar, MD (1) · Dr Bavanthi Balakrishnar (1) · Elizabeth I Buchbinder, MD (1)
PMID 31299988, PMID 31917762, PMID 33450821, PMID 35073733, PMID 35927710, PMID 36047545, PMID 36464584, PMID 36585700, PMID 36648215, PMID 37754485, PMID 38783238, PMID 39469641, PMID 40313865, PMID 40715648, PMID 41313559, PMID 41420791, PMID 42062531, PMID 42476727
2023 (1), R44CA217591 (1)